Literature DB >> 12490527

Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein.

Haibing Jiang1, Frederick C Nucifora, Christopher A Ross, Donald B DeFranco.   

Abstract

Huntington's Disease belongs to the CAG repeat family of neurodegenerative diseases and is characterized by the presence of an expanded polyglutamine (polyQ) repeat in the huntingtin (htt) gene product. PolyQ-expanded htt accumulates within large aggregates that are found in various subcellular compartments, but are more often localized within the nucleus. It has been suggested that the sequestration of proteins essential to cell viability may be one mechanism that accounts for toxicity generated by polyQ-expanded proteins. Nuclear inclusions containing polyQ-expanded htt recruit the transcriptional cofactor, CREB-binding protein (CBP). PolyQ toxicity appears to involve alterations of gene transcription and reduced neuronal cell viability. In the HT22 hippocampal cell line, we find that toxicity within individual cells induced by polyQ-expanded htt, as revealed by a TUNEL assay, is associated with the localization of the mutant htt within either nuclear or perinuclear aggregates. However, in addition to CBP recruitment, we show here that CBP ubiquitylation and degradation can be selectively enhanced by polyQ-expanded htt. Thus, selected substrates may be directed to the ubiquitin/proteasome-dependent protein degradation pathway in response to polyQ-expanded htt within the nucleus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490527     DOI: 10.1093/hmg/ddg002

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

Review 3.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

Review 4.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 5.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

6.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

7.  Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration.

Authors:  Caroline Rouaux; Natasa Jokic; Corinne Mbebi; Stephanie Boutillier; Jean-Philippe Loeffler; Anne-Laurence Boutillier
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

8.  Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis.

Authors:  Heather R Pelzel; Cassandra L Schlamp; Robert W Nickells
Journal:  BMC Neurosci       Date:  2010-05-26       Impact factor: 3.288

9.  Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Authors:  Carmela Giampà; Daunia Laurenti; Serenella Anzilotti; Giorgio Bernardi; Frank S Menniti; Francesca Romana Fusco
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

10.  What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?

Authors:  Dawn Teschendorf; Christopher D Link
Journal:  Mol Neurodegener       Date:  2009-09-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.